Eli Lilly: Stellar Q1 Earnings Put Pharma In Class Of Its Own - It's Ok To Buy TodaySeeking Alpha • 04/30/26
Eli Lilly crushes Q1 estimates, raises full-year outlook as GLP-1 sales surgeProactive Investors • 04/30/26
Demand for Weight-Loss Drugs Drove Blockbuster Results for Eli Lilly. Its Stock Is Surging.Investopedia • 04/30/26
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companiesCNBC • 04/30/26
Compared to Estimates, Lilly (LLY) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/30/26
Eli Lilly cemented its lead in the booming weight-loss drug market with huge sales gains for the first quarter, as focus shifts to new pillsWSJ • 04/30/26
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicinesPRNewsWire • 04/30/26
Eli Lilly will report first quarter earnings before the bell. Here's what Wall Street expectsCNBC • 04/30/26
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 04/30/26